• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B/A filed by CryoLife, Inc. (Amendment)

    1/6/22 11:45:40 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care
    Get the next $CRY alert in real time by email
    8-A12B/A 1 cry-202201068a12ba.htm 8-A12B/A Form 8-KA

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    

    FORM 8-A/A

    

    (Amendment No. 1)

    

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR (g) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    

    CryoLife, Inc.

    (Exact name of registrant as specified in its charter)

    

    

     

    Delaware

    59-2417093

    (State of incorporation or organization)

    (I.R.S. Employer Identification No.)

    

    1655 Roberts Boulevard, N.W.

    Kennesaw, Georgia

    30144

    (Address of principal executive officers)

    (Zip Code)

    

    Securities to be registered pursuant to Section 12(b) of the Act:

    

    Title of each class

    to be so registered

    Name of each exchange on which

    each class is to be registered

    

     

    Common Stock, par value $0.01 per share

    The New York Stock Exchange

    

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.☒

    

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.☐

    

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.☐

    

    

    Securities Act registration statement or Regulation A offering statement file number to which this form relates: __________________ (if applicable)

    

    Securities to be registered pursuant to Section 12(g) of the Act:  None

    

    

    

    

     


     

    EXPLANATORY NOTE

    This Amendment No. 1 to Form 8-A (this “Amendment”) is being filed by CryoLife, Inc. (the “Company”) in connection with its change in state of incorporation from the State of Florida to the State of Delaware (the “Reincorporation”) pursuant to a plan of conversion effective January 1, 2022 (the “Plan of Conversion”). The Reincorporation, including the Plan of Conversion, was submitted to a vote of, and approved by, the Company’s stockholders at a special meeting of the stockholders of the Company held on November 16, 2021, as set forth in the Company’s definitive proxy statement on Schedule 14A as filed with the Securities and Exchange Commission (the “SEC”) on October 7, 2021 (the “Definitive Proxy Statement”).

    The Reincorporation was accomplished by filing:  (i) Articles of Conversion with the Department of State of the State of Florida (the “Florida Articles of Conversion”); (ii) a Certificate of Conversion with the Secretary of State of the State of Delaware (the “Delaware Certificate of Conversion”); and (iii) a Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Delaware Certificate of Incorporation”). In connection with the Reincorporation, the Company’s Board of Directors adopted new bylaws in the form attached to the Plan of Conversion, which are as were set forth in the Definitive Proxy Statement (the “Delaware Bylaws”).

    The Company hereby amends the following items and exhibits of its Form 8-A originally filed with the SEC on July 2, 1997 regarding the description of common stock as set forth herein.

    Item 1.  Description of Registrant’s Securities to be Registered.

    Description of Capital Stock

    The Company is authorized to issue up to 75,000,000 shares of common stock, par value $0.01 per share (“Common Stock”), and 5,000,000 shares of preferred stock, par value $0.01 per share (“Preferred Stock”).

    Common Stock

    Holders of Common Stock are entitled to one vote per share of Common Stock held of record on all matters to be voted upon by the Company’s stockholders generally. Holders of Common Stock are not entitled to cumulative voting rights.

    Holders of Common Stock are entitled to receive, on a pro rata basis, such dividends and distributions, if any, as may be declared from time to time by the Board of Directors out of funds legally available therefor, subject to any preferential dividend right of any issued and outstanding shares of Preferred Stock. In the event of liquidation, dissolution or winding up of the Company, after payment of creditors, holders of Common Stock are entitled to share ratably in all assets of the Company, subject to the payment of any liquidation preference of any issued and outstanding shares of Preferred Stock. Furthermore, holders of Common Stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of the Company’s securities. The shares of Common Stock currently outstanding are validly issued, fully paid and non-assessable.

    Preferred Stock

    The Board of Directors of the Company is empowered, without approval of the Company’s stockholders, to cause shares of Preferred Stock to be issued in one or more series and to fix and determine the relative rights and preferences of the shares of any such series, subject to the limitations of the General Corporation Law of the State of Delaware (the “DGCL”). Because the


     

    Board of Directors has the power to establish the preferences and rights of each series, it may afford the holders of any series of Preferred Stock rights and preferences, voting or otherwise, senior to the rights of holders of Common Stock.

    While providing desirable flexibility for possible acquisitions and other corporate purposes, and eliminating delays associated with a stockholder vote on specific issuances, the issuance of Preferred Stock could adversely affect the voting, dividend and liquidation rights of holders of Common Stock.

    Certificate of Incorporation and Bylaws

    Certain provisions of the Company’s Certificate of Incorporation, Bylaws and the DGCL, which are summarized below, could have the effect of making it more difficult to change the composition of the Company’s Board of Directors or for any person or entity to acquire control of the Company.

    Preferred Stock

    As noted above, the Board of Directors may issue Preferred Stock without stockholder approval.  Consequently, the Company’s Preferred Stock could be issued quickly and utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of the Company or make removal of management and directors more difficult.

    Special Meetings

    Pursuant to the Certificate of Incorporation and Bylaws, special meetings of the stockholders may be called only by the President or Secretary at the request in writing of a majority of the Board of Directors then in office or at the request in writing of stockholders owning not less than 50% of all votes entitled to be cast at the special meeting. Only business within the purpose or purposes described in the special meeting notice may be conducted at the special meeting.

    Prohibition of Stockholder Action Without a  Meeting

    Pursuant to the Certificate of Incorporation, the Company’s stockholders may not take action by written consent. Any and all action by the stockholders must be taken at either the annual stockholders’ meeting or at a special stockholders’ meeting.

    Advance Notice of Stockholder Proposals and Nominations for Directors

    Stockholders who seek to nominate directors or to bring business before a stockholder meeting must comply with specified timing requirements and submit to the Company certain information in advance of such meeting, as set forth in the Bylaws. These provisions may impede a stockholder’s ability to bring matters before an annual or special meeting or make nominations for directors.

    Exclusive Forum Provision

    The Certificate of Incorporation includes a provision providing that, unless the Company consents to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on the Company’s behalf, any action asserting a claim of breach of fiduciary duty owed by any of the Company’s stockholders, directors, officers, or other employees to the Company or to its stockholders, and any civil action to interpret, apply, or enforce any provision of the DGCL, any civil action to interpret, apply, enforce, or determine the validity of the provisions of the Certificate of Incorporation or the Bylaws, or any action asserting a claim governed by the internal affairs doctrine; provided, however, in the event that the Court of Chancery of the State of Delaware lacks


     

    jurisdiction over such action, the sole and exclusive forum for such action shall be another state or federal court located within the State of Delaware, in all cases, subject to such court having personal jurisdiction over the indispensable parties named as defendants. Additionally, the Certificate of Incorporation provides that the federal district courts of the United States shall be the sole and exclusive forum for causes of action arising under the Securities Act of 1933, as amended. The Certificate of Incorporation also provides that the exclusive forum provision does not impact the exclusive federal jurisdiction of the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, such actions under which must be brought in the federal district courts of the United States.

    The exclusive forum provision may have the effect of discouraging lawsuits against the Company’s directors and officers.

    Delaware Anti-Takeover Law

    The Company is subject to Section 203 of the DGCL. Under Section 203, certain “business combinations” between a Delaware corporation whose stock is listed on a national securities exchange or held of record by more than 2,000 stockholders and an “interested stockholder” are prohibited for a three-year period following the date that such stockholder became an interested stockholder, unless:

    ·

    the corporation has elected in its certificate of incorporation not to be governed by Section 203;

    ·

    the business combination or the transaction which resulted in the stockholder becoming an interested stockholder was approved by the board of directors of the corporation before the date of the business combination or the date such stockholder became an interested stockholder, as applicable;

    ·

    upon consummation of the transaction that made such stockholder an interested stockholder, the interested stockholder owned at least 85% of the “voting stock” (as defined in Section 203) of the corporation outstanding at the commencement of the transaction excluding voting stock owned by directors who are also officers or held in employee benefit plans in which the employees do not have a confidential right to tender stock held by the plan in a tender or exchange offer; or

    ·

    the business combination is approved by the board of directors and by the stockholders (acting at a meeting and not by written consent) by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not “owned” (as defined in Section 203) by the interested stockholder.

    The three-year prohibition also does not apply to some business combinations proposed by an interested stockholder following the announcement or notification of an extraordinary transaction involving the corporation and a person who had not been an interested stockholder during the previous three years or who became an interested stockholder with the approval of a majority of the corporation’s directors. The term “business combination” is defined generally to include mergers or consolidations between a Delaware corporation and an interested stockholder, transactions with an interested stockholder involving the assets or stock of the corporation or its majority-owned subsidiaries and transactions which increase an interested stockholder’s percentage ownership of stock, or other transaction resulting in a financial benefit to the interested stockholder. The term “interested stockholder” is defined generally as those stockholders who become beneficial owners of 15% or more of a Delaware corporation’s voting stock, together with the affiliates or associates of that stockholder.


     

    Item 2.  Exhibits.

    The following exhibits to this Amendment are incorporated by reference from the documents specified, which have been filed with the SEC.

    

     

    Exhibit
    Number


    Description

    2.1

    Plan of Conversion, effective January 1, 2022 (Filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 4, 2022 and incorporated by reference herein)

    3.1

    Delaware Certificate of Conversion, effective January 1, 2022 (Filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 4, 2022 and incorporated by reference herein)

    3.2

    Delaware Certificate of Incorporation, effective January 1, 2022 (Filed as Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed with the SEC on January 4, 2022 and incorporated by reference herein)

    3.3

    Delaware Bylaws, effective January 1, 2022 (Filed as Exhibit 3.3 to the Company’s Current Report on Form 8-K, filed with the SEC on January 4, 2022 and incorporated by reference herein)

    3.4

    Florida Articles of Conversion, effective January 1, 2022 (Filed as Exhibit 3.4 to the Company’s Current Report on Form 8-K, filed with the SEC on January 4, 2022 and incorporated by reference herein)

    

     


     

    SIGNATURE

    

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

    

    

     

    ], 2022

     

     

     

     /s/ D. Ashley Lee

     

    Officer and Chief Financial Officer

     

    

     

     

    Date: January 6, 2022

    CRYOLIFE, INC.

     

     

    By:  /s/ D. Ashley Lee                             

            D. Ashley Lee

            Executive Vice President, Chief Operating
            Officer and Chief Financial Officer

    


    Get the next $CRY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRY

    DatePrice TargetRatingAnalyst
    1/7/2022$29.00 → $25.00Equal-Weight
    Morgan Stanley
    7/30/2021$31.00 → $32.00Equal-Weight
    Morgan Stanley
    7/30/2021$38.00 → $39.00Buy
    Needham
    7/15/2021$31.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Cryolife with a new price target

    Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $25.00 from $29.00 previously

    1/7/22 8:57:55 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    Morgan Stanley reiterated coverage on Cryolife with a new price target

    Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $32.00 from $31.00 previously

    7/30/21 11:55:50 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    Needham reiterated coverage on Cryolife with a new price target

    Needham reiterated coverage of Cryolife with a rating of Buy and set a new price target of $39.00 from $38.00 previously

    7/30/21 6:09:23 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CryoLife Announces Corporate Rebranding and Changes Name to Artivion

    ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY."

    1/18/22 8:10:00 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum

    ATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available. For more information on the company, please visit CryoLife's website, www.cryolife.com, on the Investor Relations page. About CryoLife, Inc.Headquartered in suburban Atlanta, Georgia,

    11/9/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Reports Third Quarter 2021 Financial Results

    ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina

    11/4/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    SEC Filings

    View All

    $CRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CryoLife Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ARTIVION, INC. (0000784199) (Filer)

    1/20/22 4:36:16 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 8-A12B/A filed by CryoLife, Inc. (Amendment)

    8-A12B/A - CRYOLIFE INC (0000784199) (Filer)

    1/6/22 11:45:40 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - CRYOLIFE INC (0000784199) (Filer)

    1/4/22 3:58:05 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Horton Amy sold $46,422 worth of shares (2,500 units at $18.57) and gifted 1,500 shares, decreasing direct ownership by 4% to 85,282 units

    4 - CRYOLIFE INC (0000784199) (Issuer)

    12/10/21 4:13:01 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Davis John E bought $10,398 worth of shares (600 units at $17.33), increasing direct ownership by 0.83% to 72,499 units

    4 - CRYOLIFE INC (0000784199) (Issuer)

    12/1/21 4:14:23 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Semedo Anthony B. was granted 4,992 shares and bought $260,400 worth of shares (15,000 units at $17.36)

    4 - CRYOLIFE INC (0000784199) (Issuer)

    11/30/21 4:40:44 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Financials

    Live finance-specific insights

    View All

    CryoLife Reports Third Quarter 2021 Financial Results

    ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina

    11/4/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results

    ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc. To participate in the conference call dial 862-298-0702 a few minutes

    10/20/21 4:10:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    CryoLife Reports Second Quarter 2021 Financial Results

    ATLANTA, July 29, 2021 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $76.1 million in the second quarter 2021 versus $53.8 million in the second quarter of 2020, an increase of 42% on a GAAP basis and 35% on a non-GAAP proforma constant currency basis Net loss was ($2.2) million, or ($0.06) per share, in the second quarter of 2021 Non-GAAP net income was $4.8 million, or $0.12 per share, in the second quarter of 2021 CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today i

    7/29/21 4:05:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Leadership Updates

    Live Leadership Updates

    View All

    Anthony Semedo Joins CryoLife Board of Directors

    ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to its Board of Directors effective October 1, 2021. "We are thrilled to welcome Tony, a leader in the aortic space, to our board of directors," commented Pat Mackin, Chairman, President, and Chief Executive Officer. "Tony's demonstrated ability to lead, grow, and integrate diversified global divisions in the medical device space as well as his experience managing robust R&D, quali

    9/22/21 4:25:00 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    $CRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - CRYOLIFE INC (0000784199) (Subject)

    2/12/21 8:48:51 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed

    SC 13G - CRYOLIFE INC (0000784199) (Subject)

    2/11/21 2:02:44 PM ET
    $CRY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CRYOLIFE INC (0000784199) (Subject)

    2/10/21 10:46:47 AM ET
    $CRY
    Medical/Dental Instruments
    Health Care